Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939597 · ClinicalTrials.gov registry record · Phase 3
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
A Phase 3 study of Central Nervous System Carcinoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT04939597 is a Phase 3 study of Central Nervous System Carcinoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 192 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT04939597, a Phase 3 study of Central Nervous System Carcinoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Cognitive Assessment
- DRUG Placebo Administration
- DRUG Memantine Hydrochloride
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- Loma Linda University Medical Center - Loma Linda
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Valley Children's Hospital - Madera
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
- UCSF Medical Center-Mission Bay - San Francisco
Arizona
- Banner Children's at Desert - Mesa
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
Colorado
- Children's Hospital Colorado - Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver
Alabama
- Children's Hospital of Alabama - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939597
The ClinicalTrials.gov registry entry for NCT04939597 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04939597 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04939597 about?
NCT04939597 is a clinical study titled "A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor". This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (...
What is the current status of trial NCT04939597?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2022-05-10. Estimated completion is 2027-09-30.
What conditions does trial NCT04939597 study?
This clinical trial studies the following conditions: Central Nervous System Carcinoma.
What interventions are being tested in trial NCT04939597?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cognitive Assessment (PROCEDURE), Placebo Administration (DRUG), Memantine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04939597?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939597 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.